



# The 29th JFCR-ISCC

## New Antitumor Agents under development in the US, Europe and Japan

2025

December 10 (Wed) 13:00 - 19:30

December 11 (Thu) 9:00 - 16:50

Miraikan

National Museum of Emerging Science and Innovation  
2-3-6, Aomi, Koto-ku, Tokyo, Japan

### December 10 (Wed)

#### Session 1

13:00~

Antibody therapeutics: Targeting to functional design

Yosuke Yoshida

Daiichi Sankyo Co., Ltd.

Clinical development of R-DXd, a novel CDH6-targeting DXd-ADC

Hiroki Hayashi

Chugai Pharmaceutical Co., Ltd.

ROSE12, a novel ATP-dependent FcγRs affinity-enhanced anti-CTLA-4 switch antibody for tumour-selective enhancement of anti-tumour immunity

#### Meet-the-Expert Session 1

Ryan B. Corcoran

MGH Cancer Center / Harvard Med. Sch.

Combination strategies to increase the efficacy of KRAS inhibition

#### Session 2

Targeting RAS-driven cancers

Hiromichi Ebi

Aichi Cancer Center Research Institute

Overcoming resistance to KRAS inhibitors

Mallika Singh & Clay Gustafson

Revolution Medicine

Targeting the oncogenic state of RAS with Tri-Complex inhibitors

Pankaj Punia

Astellas Pharma Oncology Development, Addlestone, UK

Development spotlight: Advancing KRAS-targeted therapies through ASP5834 and ASP3082

#### Poster Flash Talks, Poster Viewing & Networking

### December 11 (Thu)

#### Session 3

9:00~

Mapping cancer at single-cell resolution

Ignacio Vazquez-Garcia

Harvard Med. Sch. / MGH

Tracing cancer dynamics at single-cell resolution

Sydney M. Shaffer

Univ. of Pennsylvania

Unraveling how cancer cells escape treatment over time

Ayako Suzuki

Univ. of Tokyo

Elucidating aberrant tumor cell and microenvironment status in spatial and single-cell omics analysis

#### Meet-the-Expert Session 2

Liron Bar-Peled

MGH Cancer Center / Harvard Med. Sch.

Systematic targeting of protein complexes with molecular COUPLRs

#### Luncheon Seminar

(Supported by



#### Session 4

Groundbreaking advances in cancer immunotherapy

Yosuke Togashi

Okayama Univ.

'Mitochondrial Hijack' in the tumor microenvironment

Keisuke Watanabe

Natl. Cancer Ctr.

Engineering CARs for T-cell malignancies and solid tumors

Taha Merghoub

Weill Cornell Medicine

Rewiring tumor immunity to reverse checkpoint blockade resistance

#### Session 5

AI & Quantum technologies driven drug development

Kentaro Yamamoto

Quantinuum K.K.

Quantum computing: pushing the boundary of computational chemistry

Reiji Teramoto

Chugai Pharmaceutical Co., Ltd.

Harnessing the power of ML/AI technologies in antibody drug discovery

Contact: Cancer Chemotherapy Center of JFCR

Mail: [jfcr-iscc@ml.jfcr.or.jp](mailto:jfcr-iscc@ml.jfcr.or.jp)

HP: <https://iscc.umin.jp/>



The 29th JFCR-ISCC is supported by following companies: MSD K.K., Kyowa Kirin Co., Ltd., Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., TOPPAN Holdings Inc.